Monoclonal Antibodies in Alzheimer's Disease: Advances, Challenges, and Insights from a Narrative Review

Our analysis of studies on mAb therapy for AD concluded that these new therapies significantly impact the reduction of amyloid plaques and the slowing of cognitive decline in the early stages of the disease. Nevertheless, these alternative interventions present new risks and still need to prove their clinical applicability in more robust studies, particularly regarding safety, infrastructure, and costs. Therefore, further research should aim to address these challenges in the fight against AD using mAbs.